Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of Henagliflozin and Simvastatin
NCT03329118Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Maximum plasma concentration (Cmax) of SHR3824 at Day 8, Area under the plasma concentration-time curve (AUC) of SHR3824 at Day 8 and 3 more. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03329118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329118.